Join Growin Stock Community!

Artiva biotherapeutics, inc.ARTV.US Overview

US StockHealthcare
(No presentation for ARTV)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ARTV AI Insights

ARTV Overall Performance

ARTV AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ARTV Recent Performance

-6.70%

Artiva biotherapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ARTV PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ARTV Key Information

ARTV Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ARTV Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Price of ARTV

ARTV FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ARTV Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
214.51
PB Ratio
1.04
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-26045.02%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
214.51
PB Ratio
1.04
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-26045.02%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ARTV's latest earnings report released?

    The most recent financial report for Artiva biotherapeutics, inc. (ARTV) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ARTV's short-term business performance and financial health. For the latest updates on ARTV's earnings releases, visit this page regularly.

  • How much debt does ARTV have?

    As of the end of the reporting period, Artiva biotherapeutics, inc. (ARTV) had total debt of 11.69M, with a debt ratio of 0.08. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ARTV have?

    At the end of the period, Artiva biotherapeutics, inc. (ARTV) held Total Cash and Cash Equivalents of 25.97M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ARTV's EPS continuing to grow?

    According to the past four quarterly reports, Artiva biotherapeutics, inc. (ARTV)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.88. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ARTV?

    Artiva biotherapeutics, inc. (ARTV)'s Free Cash Flow (FCF) for the period is -19.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 69.14% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ARTV?

    The latest valuation data shows Artiva biotherapeutics, inc. (ARTV) has a Price-To-Earnings (PE) ratio of -1.23 and a Price/Earnings-To-Growth (PEG) ratio of -0.71. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.